Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;55(8):1031-46.
doi: 10.1093/cid/cis688. Epub 2012 Aug 13.

White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens

Infectious Diseases Society of America  1
Collaborators, Affiliations

White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens

Infectious Diseases Society of America. Clin Infect Dis. 2012 Oct.

Abstract

There is a critical need for new pathways to develop antibacterial agents to treat life-threatening infections caused by highly resistant bacteria. Traditionally, antibacterial agents have been studied in noninferiority clinical trials that focus on one site of infection (eg, pneumonia, intra-abdominal infection). Conduct of superiority trials for infections caused by highly antibiotic-resistant bacteria represents a new, and as yet, untested paradigm for antibacterial drug development. We sought to define feasible trial designs of antibacterial agents that could enable conduct of superiority and organism-specific clinical trials. These recommendations are the results of several years of active dialogue among the white paper's drafters as well as external collaborators and regulatory officials. Our goal is to facilitate conduct of new types of antibacterial clinical trials to enable development and ultimately approval of critically needed new antibacterial agents.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of a hierarchical noninferiority–superiority study.
Figure 2.
Figure 2.
Flow diagram depicting trial designs based on randomization before or after knowing the infecting pathogen. Abbreviation: XDR/PDR, extreme drug resistant/pandrug resistant.
Figure 3.
Figure 3.
Flow diagram of a nested superiority–noninferiority trial. Abbreviation: XDR/PDR, extreme drug resistant/pandrug resistant.
Figure 4.
Figure 4.
Flow diagram of a historically controlled superiority trial. Abbreviation: XDR/PDR, extreme drug resistant/pandrug resistant.
Figure 5.
Figure 5.
Relationship between drug exposure and response to therapy. The treatment effect is the difference between maximum and minimum drug effect. The y-intercept of the functional relationship between exposure and response is an estimate of the placebo response. Abbreviations: PK-PD, pharmacokinetics-pharmacodynamics; AUC:MIC, area under the curve–minimum inhibitory concentration ratio. Figure adapted from Ambrose PG, et al, Lancet Infect Dis 2012; 12:265–6.
See this image and copyright information in PMC

References

    1. Falagas ME, Bliziotis IA. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;29:630–6. - PubMed
    1. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. 2008;32:450–4. - PubMed
    1. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009;30:257–63. - PubMed
    1. Hoffmann MS, Eber MR, Laxminarayan R. Increasing resistance of Acinetobacter species to imipenem in United States hospitals, 1999–2006. Infect Control Hosp Epidemiol. 2010;31:196–7. - PubMed
    1. Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009;53:3628–34. - PMC - PubMed

MeSH terms

Substances